| What it is | A combination of the investigational WEE1 inhibitor azenosertib with carboplatin in platinum‑resistant ovarian cancer, evaluated in Part 1 of the NCT04516447 study. | Investigational regimen pairing azenosertib with pegylated liposomal doxorubicin in the same study. | Investigational combination of azenosertib and paclitaxel evaluated in Part 1. | Investigational combination of azenosertib and gemcitabine tested in Part 1. | Investigational combination of azenosertib and bevacizumab evaluated in Part 2 (dose‑escalation/expansion) of the study. | Usual systemic therapies for platinum‑resistant ovarian cancer include single‑agent chemotherapy (PLD, paclitaxel, gemcitabine), bevacizumab plus chemotherapy, and other targeted options recommended by clinical guidelines. |
|---|
| Role in the trial | One of several investigational arms within Phase 1 evaluating safety and dose of the combination. | Evaluated as one of the combination partners to assess tolerability and dose recommendations. | Included to determine safety and dosing when combined with paclitaxel. | Tested to identify tolerable combination dose with gemcitabine. | Assessed in a separate cohort (Part 2) to define dose in combination with bevacizumab. | Represents treatment approaches commonly used outside of trials at this disease stage. |
|---|
| Primary use | Investigational therapy to explore safety and optimal dosing in combination with carboplatin. | Investigational combination aimed at establishing tolerability and dosing with PLD. | Used to determine safety and dose with paclitaxel backbone. | Designed to identify dose and safety profile with gemcitabine. | Investigational dosing evaluation of azenosertib paired with bevacizumab. | Established systemic therapy options for platinum‑resistant ovarian cancer used in routine clinical practice. |
|---|
| How it is given or performed | Azenosertib given orally in combination with intravenous carboplatin as dosing regimens established in protocol. | Oral azenosertib administered alongside intravenous pegylated liposomal doxorubicin per study protocol. | Combination of oral azenosertib with intravenous paclitaxel scheduled per trial. | Oral azenosertib plus intravenous gemcitabine per Part 1 design. | Oral azenosertib combined with intravenous bevacizumab per dose escalation cohort. | These options include intravenous single‑agent chemotherapy or chemotherapy plus bevacizumab, given per standard dosing schedules. |
|---|
| Evidence status | Safety and recommended dosing are under investigation; no mature efficacy data reported yet. | Efficacy data are not yet reported; study is dose‑finding. | No efficacy data available yet from this phase 1 combination study. | Efficacy has not yet been established in this early‑phase combination. | Still exploring safety and dose; no efficacy outcomes available yet. | Evidence supports modest response rates from single‑agent chemo and some benefit from bevacizumab combinations in PROC. |
|---|
| Important risks | Safety profile under evaluation; risks not yet fully defined. | Safety and tolerability remain unknown pending study results. | Safety data are not yet available; tolerability remains to be reported. | Safety profile not yet established in this combination context. | Safety and tolerability remain under investigation for this regimen. | Known toxicities include cytopenias, gastrointestinal and infusion‑related effects; bevacizumab adds risks like hypertension and bleeding. |
|---|
| Important limitations | Early‑phase data only; dose and safety results pending; no efficacy or comparative outcomes yet. | Limited to dosing assessment in a small safety cohort, with no efficacy evidence yet. | No mature clinical outcomes; results may not generalize beyond early trial setting. | Findings limited to small early‑trial exposure; lacks effectiveness data and long‑term outcomes. | Dose escalation focus limits generalizability; efficacy and safety conclusions await later‑phase data. | Response rates are generally modest and often short‑lived in platinum‑resistant disease. |
|---|
